Literature DB >> 25865258

Combining BRAF(V) (600E) inhibition with modulators of the mitochondrial bioenergy metabolism to overcome drug resistance in metastatic melanoma.

Elisabeth Livingstone1, Suzanne Swann2, Carmen Lilla3, Dirk Schadendorf1, Alexander Roesch1.   

Abstract

Entities:  

Keywords:  melanoma; mitochondria; oxidative phosphorylation; phenformin; resistance

Mesh：

Substances：

Year:  2015        PMID： 25865258     DOI： 10.1111/exd.12718

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN： 0906-6705            Impact factor:   3.960


× No keyword cloud information.
  10 in total

1.  Feeling energetic? New strategies to prevent metabolic reprogramming in melanoma.

Authors:  Daniel Verduzco; Keith T Flaherty; Keiran S M Smalley
Journal:  Exp Dermatol       Date:  2015-07-14       Impact factor: 3.960

Review 2.  Integration of Mitochondrial Targeting for Molecular Cancer Therapeutics.

Authors:  Philippe Marchetti; Pierre Guerreschi; Laurent Mortier; Jerome Kluza
Journal:  Int J Cell Biol       Date:  2015-12-02

3.  A Comprehensive Characterization of Mitochondrial Genome in Papillary Thyroid Cancer.

Authors:  Xingyun Su; Weibin Wang; Guodong Ruan; Min Liang; Jing Zheng; Ye Chen; Huiling Wu; Thomas J Fahey; Minxin Guan; Lisong Teng
Journal:  Int J Mol Sci       Date:  2016-10-10       Impact factor: 5.923

4.  Inhibition of retinoic acid receptor β signaling confers glycolytic dependence and sensitization to dichloroacetate in melanoma cells.

Authors:  Cecilie Abildgaard; Christina Dahl; Ahmad Abdul-Al; Annette Christensen; Per Guldberg
Journal:  Oncotarget       Date:  2017-08-24

5.  Therapeutic potential of the metabolic modulator phenformin in targeting the stem cell compartment in melanoma.

Authors:  Tiziana Petrachi; Alessandra Romagnani; Adriana Albini; Caterina Longo; Giuseppe Argenziano; Giulia Grisendi; Massimo Dominici; Alessia Ciarrocchi; Katiuscia Dallaglio
Journal:  Oncotarget       Date:  2017-01-24

Review 6.  Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management.

Authors:  Ping Jin; Jingwen Jiang; Li Zhou; Zhao Huang; Edouard C Nice; Canhua Huang; Li Fu
Journal:  J Hematol Oncol       Date:  2022-07-18       Impact factor: 23.168

Review 7.  Elesclomol: a copper ionophore targeting mitochondrial metabolism for cancer therapy.

Authors:  Peijie Zheng; Chuntao Zhou; Liuyi Lu; Bin Liu; Yuemin Ding
Journal:  J Exp Clin Cancer Res       Date:  2022-09-12

8.  Multi-Omics Analysis Revealed a Significant Alteration of Critical Metabolic Pathways Due to Sorafenib-Resistance in Hep3B Cell Lines.

Authors:  Kholoud Y I Abushawish; Sameh S M Soliman; Alexander D Giddey; Hamza M Al-Hroub; Muath Mousa; Karem H Alzoubi; Waseem El-Huneidi; Eman Abu-Gharbieh; Hany A Omar; Sara M Elgendy; Yasser Bustanji; Nelson C Soares; Mohammad H Semreen
Journal:  Int J Mol Sci       Date:  2022-10-09       Impact factor: 6.208

Review 9.  Metabolic Interplay between the Immune System and Melanoma Cells: Therapeutic Implications.

Authors:  Alice Indini; Francesco Grossi; Mario Mandalà; Daniela Taverna; Valentina Audrito
Journal:  Biomedicines       Date:  2021-05-26

10.  Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma.

Authors:  Muhammad Zubair Afzal; Rima R Mercado; Keisuke Shirai
Journal:  J Immunother Cancer       Date:  2018-07-02       Impact factor: 13.751
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.